Pheron Therapeutics

Pheron Therapeutics is a South Korean biotechnology company specializing in the development of next-generation immuno-oncology therapies through its proprietary Sialidase-Antibody Conjugate (SAC) platform. The company's technology focuses on "glyco-editing" the tumor microenvironment by using antibody-guided sialidases to remove immunosuppressive sialic acids from the surface of cancer cells. This process disrupts the Siglec-sialic acid signaling pathway, thereby reactivating innate and adaptive immune cells to attack the tumor. Pheron's lead programs target well-validated tumor antigens such as HER2 and TROP2, aiming to provide more effective treatments for patients with various solid tumors.